Last reviewed · How we verify

Thiocarb — Competitive Intelligence Brief

Thiocarb (DITIOCARB) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ditiocarb. Area: Other.

phase 2 ditiocarb Cytochrome P450 2E1, Gasdermin-D, Histone-lysine N-methyltransferase EHMT1 Other Small molecule Live · refreshed every 30 min

Target snapshot

Thiocarb (DITIOCARB). Thiocarb works by inhibiting the activity of Gasdermin-D, a protein that plays a key role in the inflammatory response and cell death.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Thiocarb TARGET DITIOCARB phase 2 ditiocarb Cytochrome P450 2E1, Gasdermin-D, Histone-lysine N-methyltransferase EHMT1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ditiocarb class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Thiocarb — Competitive Intelligence Brief. https://druglandscape.com/ci/ditiocarb. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing